Nova Eye Medical (ASX:EYE) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 25, 2026)


ASX:EYE Nova Eye Medical Ltd ASX:EYE
55 GF Score
Price A$0.10
GF Value A$0.18
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Nova Eye Medical Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Nova Eye Medical's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

ASX:EYE vs ABT, SYK, MDT: Margin of Safety % (DCF Earnings Based) Comparison

For the Medical Devices subindustry, Nova Eye Medical's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nova Eye Medical Margin of Safety % (DCF Earnings Based) vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nova Eye Medical's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Nova Eye Medical's Margin of Safety % (DCF Earnings Based) falls into.


ASX:EYE
55GF Score
Nova Eye Medical Ltd ASX:EYE
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Nova Eye Medical (ASX:EYE) Overvalued in 2026?

Based on GuruFocus' analysis, Nova Eye Medical stock appears to be undervalued. The current stock price of A$0.10 is trading 43.1% below its estimated GF Value™ of A$0.18. GuruFocus considers Nova Eye Medical to be Possible Value Trap.

Key valuation signals for ASX:EYE:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: A$0.18 vs. price of A$0.10 (43.1% below fair value)
  • GF Score™: 55/100 with 4 warning signs

No single metric tells the full story. See the ASX:EYE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nova Eye Medical Business Description

Address 107 Rundle Street, Kent Town, Adelaide, SA, AUS, 5067
Nova Eye Medical Ltd develops and sells surgical devices for the treatment of glaucoma, a cause of blindness. In addition, the company is involved in the commercialisation of the subthreshold nano-pulse ophthalmic laser, 2RT, for the treatment of retinal disease via the AlphaRET segment. The company's reportable segments are: Glaucoma Surgical Devices and AlphaRET. The majority of its revenue is generated from the Glaucoma Surgical Devices segment, which is involved in the design, manufacture, marketing, and sale of the iTrack, iTrack Advance, and the Molteno3 glaucoma surgical device. These are all single-use surgical devices. Geographically, the company generates maximum revenue from the United States of America, followed by Europe, the Asia Pacific, Other regions, and Australia.
55GF Score

Get the complete analysis for ASX:EYE

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.10
Price
A$0.18
GF Value